# 1. Financial Performance ## A. Key Figures * Revenue from Operations: ₹580 Cr Q3 FY'26 (+10.9%) · ₹1,699.6 Cr 9M FY'26 (+9.6%) * EBITDA: ₹62.6 Cr Q3 FY'26 (+22.8%) · ₹196.1 Cr 9M FY'26 (+24.8%) * EBITDA Margin: **10.7%** Q3 FY'26 (from 9.7%) · **11.4%** 9M FY'26 (from 10.0%) * PBT before Exceptional Items: ₹38.8 Cr Q3 FY'26 (+39.3%) · ₹124.8 Cr 9M FY'26 (+34.2%) * **Segment Revenue Mix (Q3):** **Pharma: ₹356 Cr (61%)** · **Chemicals: ₹224 Cr (39%)** ## B. Revenue Growth * **Resilient Top-Line Performance:** Revenue growth sustained despite global macro headwinds, underpinned by diversified model and disciplined execution. * **Pharma-Led Momentum:** Strong volumes and geographic expansion in quality-focused markets enhanced revenue visibility and reduced concentration risk. * **Stable Segment Mix:** Pharma remains core revenue driver with **61% share**, supported by consistent customer engagement. ## C. EBITDA Margin * **Margin Expansion Achieved:** EBITDA margin improved both quarterly and year-to-date, driven by operating leverage and cost optimization. * **H2 Target Missed:** Full recovery to **13–14% H2 target** was constrained by **unexpectedly high fuel costs**, though sequential improvement expected. * **Mixed Segment Trends:** Chemical margins rose sharply on higher capacity utilization; pharma margins declined due to **lower paracetamol prices** and **para capacity underutilization (~60%)**. * **Cost Pressures Persist:** YoY cost inflation of **20%** stemmed from fuel and one-time personnel expenses, with marketing and admin costs also rising. ## D. Profitability Trends * **Sustained PBT Growth:** PBT and PBT margin expanded year-on-year in both Q3 and 9M periods, reflecting effective cost control and operational scaling. ## E. Balance Sheet * **Solid Financial Foundation:** Balance sheet remains strong, supported by healthy cash flows and conservative financial management. * **Inventory Adjustment:** Total inventory at **₹350 Cr**, with reduction primarily from lower API inventory valuation, not chemical stock build-up. --- # 2. Product & Segment Mix ## A. Key Figures * **Pharma Revenue Share:** **61%** (Q3 FY'26) vs 57% (Q3 FY'25) * **API Revenue Mix:** **64% ibuprofen** · **36% non-ibuprofen** (vs 66%/34% in Dec-24) * **Ibu Revenue:** **₹228 Cr** · **Non-Ibu Revenue:** **₹128 Cr** * **Revenue Target:** **60% APIs / 40% chemicals** (near-term, within 2 years) · **75% APIs / 25% chemicals** (long-term) ## B. Pharma vs Chemicals * **Strategic Shift Accelerating:** Pharma’s rising share reflects successful API-led transformation and growing confidence in reaching long-term mix targets. * **Capex Prioritization:** Focus remains on organic expansion via new plant on existing land; Solara ibuprofen plant acquisition not under current consideration. ## C. Ibu vs Non-Ibu APIs * **Diversification Gains Traction:** Non-ibuprofen APIs now represent a growing and strategic portion of the portfolio, driven by **metformin, pantoprazole, clopidogrel**, and **minoxidil API** rollout in Europe. * **Key Growth Levers:** **Paracetamol** and **metformin** are highlighted as primary near-term drivers, supported by facility repurposing and stable pricing. * **Portfolio Evolution:** Revenue mix shift toward non-ibuprofen APIs signals reduced concentration risk and expanded regulatory market acceptance. ## D. API Revenue Target * **Forward Integration Strategy:** CMO model for APIs (not formulations) underway, enhancing value capture; company already backward integrated in **ibu** and **para**. * **Long-Term Structural Goal:** Targeting **50-50 split between ibuprofen and non-ibuprofen APIs**, aligning with broader diversification and margin enhancement objectives. --- # 3. Capacity & Utilization ## A. Key Figures * **Pharma Utilization:** **90–95%** for Ibuprofen API · **>90%** overall pharma (excl. paracetamol) * Chemicals Utilization: **near 200%** capacity utilization · **~100%** at ethyl acetate plant * **Chemicals EBIT:** **Nearly doubled** in 9M FY26 YoY ## B. Pharma Utilization * **Strong Ibuprofen Demand:** Ibuprofen API operates at near-full capacity with **stable pricing**, reflecting resilient market positioning despite rising competition. * **High Portfolio Utilization:** Broadly elevated pharma capacity utilization underscores effective volume management, with paracetamol expansion underway. * **Margin Sensitivity:** Management highlights control over production levels, but flags **price volatility** as a key external risk to revenue and margins. ## C. Chemicals Utilization * **Structural Outperformance:** Chemicals segment demonstrated robust profitability growth, driven by **near-full capacity utilization** and strong operational execution. * **Demand & Efficiency Gains:** Stable performance underpinned by improved demand, **operational discipline**, and **throughput optimization** across the asset base. ## D. Expansion Projects * **Site Development Progress:** Environmental clearance secured for new land; ongoing coordination with national highway authorities and regulators for remaining NOCs and consents. * **Strategic Capacity Buildout:** New site will support **integrated growth in both API and chemicals**, aligning with long-term vertical integration strategy; product roadmap still in development. --- # 4. Geography & Exports ## A. Key Figures * **Non-ibu Exports:** **15–17%** of total exports * **Regulated Market Exposure:** **~15%** of non-ibu revenue from regulated markets (primarily Europe) * **Global Ibuprofen Demand Growth:** **3–4%** annually, supported by supply exits (e.g., U.S. closure) ## B. Regulated Markets * **Strategic Shift:** Growth supported by migration of non-ibu domestic products into regulated markets, leveraging new production capacity for API expansion. * **Europe Momentum:** Europe remains the core demand driver, with strong traction in pharma portfolio and non-ibuprofen APIs. ## C. EU & MENA Focus * **Geographic Expansion:** Strategic priority on EU, broader Europe, and MENA to enhance growth and sustain margins across consolidated API and chemical segments. * **Long-Term Reach:** Primary focus on Europe and MENA, with other global regions under evaluation for future entry. ## D. Export Mix * **Operational Uptick:** Multiple regulatory approvals secured, boosting exports and supporting higher asset utilization. * **Favorable Supply Dynamics:** Robust demand growth in ibuprofen amid tightening global supply, creating opportunity for market share gains. --- # 5. R&D & Pipeline Progress ## A. Patent Portfolio * **Headline:** Holds **3 process patents** (sitagliptin, vildagliptin, losartan), though none are in commercial production. * **Headline:** R&D remains active with ongoing evaluation of new product development for future patent opportunities. ## B. Product Development * **Headline:** Parallel development underway in API and chemical divisions, with dedicated teams advancing multiple products. * **Headline:** Focus on **generic molecule combinations** and differentiation for existing market molecules to build competitive advantage. ## C. Commercialization Plans * **Headline:** Achieved CEP for **minoxidil**, enabling regulated market access and planned commercialization by end-December via Unit 9. * **Headline:** Initial launch targeted at international markets; broader pipeline timelines remain undisclosed. --- # 6. Input Cost & Operational Risks ## A. Key Figures * **Exceptional Item:** **₹11.2 Cr** non-recurring provision (labor law) * **Exceptional Loss:** **₹11.21 Cr** due to labor law consolidation (gratuity/leave recalculation) ## B. Fuel Cost Pressure * **Sustained Fuel Inflation:** Power and fuel costs remain elevated post-Q2 spike, driven by **non-reduction in input prices** despite stable consumption, with rice husk facing seasonal price pressures. * **Sustainability-Compliant Fuel Mix:** Company utilizes **coal and rice husk** (agricultural byproduct) to reduce carbon footprint, supporting ESG objectives. * **Alternative Fuel Constraints:** Exploration of paddy straw limited by **trade-offs in cost efficiency and carbon impact**, while briquettes entail higher production costs versus rice husk. ## C. Nitrosamine Challenges * **Production Halted on Patent Issues:** Commercial output suspended for key molecules—vildagliptin and losartan—due to **nitrosamine impurities**, and sitagliptin due to **enzyme-related manufacturing challenges**. ## D. Labor Law Impact * **One-Time Regulatory Impact:** Significant ₹21 Cr exceptional loss from central labor code reform, which altered historical liabilities for **gratuity and earned leave**, alongside a separate ₹2 Cr provision. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Target:** **₹2,700 Cr** by FY'27 (API: ₹1,800 Cr; Chemical: ₹900 Cr) * **Q4 Revenue Forecast:** **₹600 Cr** (guidance) * **Q4 EBITDA Margin:** **~11%** (potentially slightly higher) ## B. Revenue Forecast * **Growth Roadmap:** Strategic focus on regulated markets, non-ibuprofen API expansion, and R&D to sustain **double-digit top-line growth** and shift toward higher-value products. * **Portfolio Transformation:** Targeting a **50-50 revenue split between ibuprofen and non-ibuprofen APIs by 2027**, signaling strategic diversification and reduced product concentration risk. * **Demand Resilience:** Strong capacity utilization and export momentum underpin confidence in guidance, despite global price volatility limiting precise forecasting. ## C. Margin Expectations * **Margin Recovery Underway:** Q4 EBITDA margin expected to rebound from prior shortfall, with **10–15% upside projected for FY'27** as pricing discipline replaces volume-centric strategy. * **Revised Margin Framework:** Full-year EBITDA margin outlook adjusted to **11–12%**, reflecting current market dynamics, though sustained operating efficiency improvements provide confidence in future expansion. ## D. Capex Plan * **Growth-Aligned Investment:** Capex to remain consistent with historical levels, with **majority allocation to growth initiatives** and nearly half to automation and infrastructure, supporting long-term scalability. * **Confident Execution Outlook:** Leadership affirms strong business momentum, driven by **deepening customer relationships**, **portfolio breadth**, and **operational discipline**, reinforcing guidance credibility.